In lung cancer cells, PDE5 inhibitors modulate the endocytosis probably via the increase in cGMP levels and consequently the PKG activity, enhancing the cytotoxic activity of the anti-tumoral drugs doxorubicin and cisplatin. Here, PDE5A is linked to lung carcinoma.